12 Hallmarks of Aging: What They Mean and Their Limits

The hallmarks are a map for studying why we age, not twelve diagnoses or a treatment menu. Here is what each one means, what human evidence can show and where marketing begins.

The 12 hallmarks of aging are a research map, not twelve red lights that a clinic can switch on in your blood work. That distinction may sound small, but it changes everything. It prevents the leap from “this pathway matters in an aging mouse” to “you need an infusion to correct it”.

The framework is valuable because it organises an enormous field. DNA, proteins, mitochondria, senescent cells, inflammation and the microbiome do not age in separate rooms. They influence one another, sometimes as damage and sometimes as a useful response that later becomes dysregulated.

The best way to read the list is with curiosity and a gentle hand on the brake: a mechanism is not a diagnosis, a biomarker is not a benefit, and changing a signal does not prove rejuvenation.

Editorial review: August 2026. This is educational content, not individual medical advice. Aging cannot be diagnosed or treated from this article.

Quick answer

The original 2013 paper proposed nine hallmarks; the 2023 review expanded the framework to twelve.
They are interconnected research criteria, not twelve independent causes with equal weight.
Much causal evidence comes from cells and animals; human evidence varies substantially by hallmark.
There is no validated clinical panel that measures how much of each hallmark you have.
An intervention may touch a molecular pathway without improving function, disease, disability or survival.
Exercise, prevention and good nutrition remain valuable without a rejuvenation promise.

From nine to twelve: how the map began

In 2013, Carlos López-Otín, María Blasco, Linda Partridge, Manuel Serrano and Guido Kroemer published a Cell review proposing nine tentative hallmarks of aging. The aim was to find common denominators across organisms and connect basic biology with health.

The 2023 update added disabled macroautophagy, chronic inflammation and dysbiosis. The authors describe three premises for calling a process a hallmark:

it manifests in association with age;
experimentally accentuating it accelerates aging features;
therapeutically acting on it offers an opportunity to slow, stop or reverse those features.

The third premise is often read with too much enthusiasm. “Offers an opportunity” within the evidence does not mean a safe treatment already exists for healthy people. Experiments may involve yeast, worms, flies, mice, human cells or selected patient groups. Every step between them needs its own validation.

The 12 hallmarks without turning them into diagnoses

1. Genomic instability

DNA experiences lesions, copying errors and somatic mutations. Repair, cell-cycle control and removal of damaged cells protect the organism, but the balance changes over time. Cancer, radiation, smoking and inherited repair disorders illustrate why genomic integrity matters.

The limit: there is no whole-body “age-related DNA damage” number. Studies of skin or oesophagus cannot establish that every cell collects the same annual mutation count. Healthy sleep matters, but there is no nightly phase proven to repair your entire genome or IV NAD+ infusion shown to restore it.

2. Telomere attrition

Telomeres protect chromosome ends and tend to shorten through cell division. When protection fails, cells may enter senescence, die or become unstable. Dynamics differ across tissues, cell types and telomerase activity.

The limit: longer is not always better. Some cancer cells maintain telomeres to keep dividing, and a blood measurement does not summarise every tissue. Our guide to telomeres and longevity explains why a result is not a biological expiry date.

3. Epigenetic alterations

Aging accompanies changes in DNA methylation, histones, chromatin organisation and gene expression. Some patterns are regular enough to build clocks that estimate age or population risk.

The limit: a clock does not measure the whole hallmark or tell you which treatment you need. Different models can report different ages. A small change after diet, exercise or a supplement does not prove that the body has become younger. See how to interpret epigenetic clocks.

4. Loss of proteostasis

Cells make, fold, transport and break down proteins. Chaperones, proteasomes, lysosomes and other networks maintain quality. When control deteriorates, altered proteins and aggregates associated with several diseases can accumulate.

The limit: saying one amyloid plaque “causes” Alzheimer's or a sauna corrects proteostasis compresses far more complex biology. There is no routine whole-body proteostasis score or validated heat protocol for rejuvenating it.

5. Disabled macroautophagy

Macroautophagy delivers cellular material to lysosomes for degradation and reuse. It is a dynamic flux that varies by tissue and context. The 2023 update gave it independent status within the framework.

The limit: measuring one related protein does not demonstrate complete flux. Nor is there a universal human hour at which fasting switches on cleaning in every organ. Our fasting and autophagy guide separates animal data, markers and clinical outcomes.

6. Deregulated nutrient-sensing

mTOR, AMPK, insulin/IGF-1 and sirtuins help coordinate growth, energy, repair and nutrient availability. They are not isolated switches: their activity changes with food, movement, illness, tissue and time of day.

The limit: mTOR is not always bad and AMPK is not always good. Growth, muscle building, infection responses and wound repair require different balances. Rapamycin extends life in several animal models, but that does not make it routine prevention for human aging.

7. Mitochondrial dysfunction

Mitochondria produce energy, integrate signals, participate in immunity and influence cell decisions. Age can alter their number, shape, DNA, recycling and efficiency. Some reactive species are useful signals, not simple “rust” to eliminate.

The limit: fatigue does not diagnose mitochondrial dysfunction, and one small tissue study cannot prove a universal 50% NAD+ decline between two ages. Cold exposure, CoQ10, PQQ or IV NAD+ have not been shown to rejuvenate a healthy person's mitochondria. See our guide to mitochondrial dysfunction and aging.

8. Cellular senescence

A senescent cell stops dividing and changes its activity. Senescence can limit tumours, assist development or repair and, when persistent in some contexts, alter tissues through signals such as the SASP. Not every senescent cell is the same or harmful.

The limit: there is currently no routine whole-body senescent-cell burden test. Dasatinib with quercetin, fisetin and other candidates remain experimental; small human studies have not shown general rejuvenation. Our guide to senolytics and zombie cells examines that translation.

9. Stem cell exhaustion

Tissues rely on stem and progenitor cells for renewal and repair. Age changes the cells, their niches, immune signals and metabolic environment. The pattern is not identical in blood, muscle, skin and intestine.

The limit: experiments joining the circulation of young and old animals do not show that plasmapheresis, young plasma or a cell therapy rejuvenates people. “Exhausted stem cells” is also not a diagnosis that a commercial infusion can fix.

10. Altered intercellular communication

Hormones, neurotransmitters, cytokines and cell contacts coordinate the body. Aging can change immune, neuroendocrine and metabolic networks, sometimes as compensation and sometimes harmfully.

The limit: there is no universal “anti-aging hormone balance”. Hormone therapy has specific indications, benefits and risks; it is not prescribed to correct an abstract hallmark. Removing factors from plasma also does not demonstrate that the body's communication has been rejuvenated.

11. Chronic inflammation

Persistent low-grade inflammatory activity may accompany age and relate to immunity, visceral fat, infection, disease, senescence and other processes. The term inflammaging helps researchers study those connections.

The limit: CRP, IL-6, TNF-alpha and suPAR are non-specific and change for many reasons. None measures “your inflammaging” or indicates ozone, fasting or a supplement by itself. Our inflammaging guide explains when an inflammatory signal needs clinical assessment.

12. Dysbiosis

The microbiome and its metabolites interact with immunity, the intestinal barrier, diet and medication. Age, geography, transit, food and illness all influence composition. There is no single young or ideal microbiome.

The limit: high diversity is not always health, a stool test does not calculate gut age and “30 plants a week” comes from associations rather than a universal dose that reverses dysbiosis. Avoiding unnecessary antibiotics is sensible; stopping an indicated one is not.

A network, not a scorecard with twelve boxes

The hallmarks overlap. Genomic damage can induce senescence; senescent cells can release inflammatory signals; inflammation and metabolism alter stem-cell niches; mitochondria and autophagy regulate one another. Adding twelve separate scores therefore makes little biological sense.

There are also trade-offs. Senescence, inflammation, mTOR and reactive species can serve useful functions. The issue is not simply whether a pathway is “high” or “low”, but where, how strongly, for how long and in what context. Blocking it may help in one setting and harm in another.

Can they be measured in a person?

Level	What it can provide	What it does not prove
Routine clinical care	Cardiovascular risk, metabolism, disease, symptoms, strength, mobility and function.	A direct score for the twelve hallmarks.
Research biomarkers	Telomeres, methylation, proteins, cytokines, cells or metabolites in a particular sample.	Which mechanism causes a problem or how many years you have rejuvenated.
Commercial tests	An estimate based on an algorithm or reference set.	Clinical validity, the right action or benefit from buying the linked treatment.

Aging-biomarker consortia are still working on comparability, generalisability, individual response and links to clinical outcomes. That is why a test can be interesting research without being ready to direct your treatment. Learn more in longevity biomarkers: what to measure and why.

Does targeting a hallmark slow aging?

In cells and animals, modifying some processes changes survival, function or age-related traits. That is the basis of geroscience. In humans, proof requires a defined intervention, population, comparator, outcome and timescale. A molecular marker may be one step, but it does not replace less disease, better function or safety.

Rapamycin, senolytics, partial reprogramming, microbiome manipulation and circulating factors are separate research lines. They do not form a validated clinical package. IV NAD+, ozone, plasmapheresis and orthomolecular infusions have not been shown to “cover” several hallmarks and slow aging in healthy people.

Meanwhile, movement, not smoking, vaccination, treating blood pressure or diabetes when appropriate, adequate varied food, sleep and mental-health care improve known clinical outcomes. They may influence many pathways, but we do not need to call this “hallmark reversal” to recommend it. WHO stresses that any activity is better than none and that environment also shapes functional ability.

Five questions that expose an inflated promise

Does the evidence come from people, animals or cells?
Was the outcome a mechanism, a marker or something meaningful to patients?
Is there a validated test for deciding who needs the intervention?
Are dose, duration, adverse effects and comparator known?
Does the same business sell both the test and the inevitable solution?

A rigorous assessment can review prevention, symptoms, function and risk, and explain whether a test is clinical or experimental. It cannot identify “your three dominant hallmarks” or promise that a package will reverse them. If you want help ordering real priorities, you can start an assessment with the Progevita team.

Frequently asked questions

What are the hallmarks of aging?

They are a scientific framework grouping biological processes related to aging. The 2023 Cell review proposes 12 and uses three ideas: they appear with age, experimentally worsening them accelerates aging features, and acting on them may slow or reverse those features in an experimental system. They are not twelve diseases or a clinical guideline.

Are there 9 or 12 hallmarks of aging?

The 2013 article proposed nine tentative hallmarks. The 2023 update added disabled macroautophagy, chronic inflammation and dysbiosis, bringing the total to twelve. The change shows that the framework evolves with evidence; it is not a permanently closed list.

Are the hallmarks the twelve causes of aging?

Calling them causes is convenient but too simple. They are interconnected processes that can initiate damage, respond to it or amplify it. Their relative importance changes by species, tissue, life stage and disease, and the framework assigns no causal percentage to each.

Can I find out which hallmark is most active in me?

No validated clinical test measures all twelve or identifies which one is aging your body fastest. Telomeres, epigenetic clocks, cytokines and microbiome tests capture different fragments and have limits. Clinical testing should focus on risk, disease and function when a result changes a decision.

Can reversing a hallmark rejuvenate me?

Several processes can be modified in cells or animals. In people, a changed marker does not prove rejuvenation, less disease or longer life. Clinical benefit requires meaningful outcomes, safety and durable effects, not only movement in a molecular pathway.

Which hallmark is easiest to improve?

There is no clinical ranking. Inflammation or microbiome composition can change quickly, but that does not show aging has been reversed. A CRP result or stool sample also does not represent a complete hallmark. Priority depends on each person's risk and function.

Do fasting, supplements or longevity therapies target the hallmarks?

They may alter related signals in a laboratory, but that is not enough to show slower human aging. IV NAD+, ozone, plasmapheresis, senolytics or supplements have not been shown to correct a panel of hallmarks and rejuvenate healthy people.

How should a clinic use the hallmarks?

The framework can generate hypotheses and explain why pathways are studied. It should not invent diagnoses or justify the same package for everyone. A rigorous assessment prioritises goals, risk, function, prevention and indicated treatment, and labels experimental work clearly.

Sources

Method: narrative review of the original framework and its update, biomarker consensus papers and public-health sources. Mechanisms, experimental models, human associations, markers and clinical outcomes are treated as distinct evidence levels. Data reviewed in August 2026.

The 12 Hallmarks of Aging: A Map of Evidence and Limits

Quick answer

From nine to twelve: how the map began